艾普特沃治疗将在2026年3月的两次生物技术会议上发表报告,强调其癌症疗法和相关风险. Aptevo Therapeutics to present at two biotech conferences in March 2026, highlighting its cancer therapies and associated risks.

艾普特沃治疗将在2026年3月举行的两次大型生物技术会议上发表讲话:首席执行官杰夫·拉莫斯将于3月23日的罗斯大会上发言,而米歇尔・H.尼尔森博士将于24日在BIO-Europe Spring发布会上介绍该公司三种特定分子. Aptevo Therapeutics will present at two major biotech conferences in March 2026: CEO Jeff Lamothe will speak at the Roth Conference on March 23, and Dr. Michelle H. Nelson will present on the company’s trispecific molecules at BIO-Europe Spring on March 24. 该公司使用其ADAPTIR平台开发针对固体瘤的免疫瘤疗法, 拥有两种临床和六种临前候选药物. The company, developing immune-oncology therapies for solid tumors using its ADAPTIR platforms, has two clinical and six preclinical candidates. 虽然强调了潜在的进展,但Aptevo警告说未来的结果是不确定的,因为包括临床试验成果,安全性和监管变化的风险. While highlighting potential advancements, Aptevo warns that future results are uncertain due to risks including clinical trial outcomes, safety, and regulatory changes.